{"filings":[{"id":705396,"accession_number":"0001999480-26-000016","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2026-05-28T12:18:14+00:00","items":["5.02"],"status":"ready","headline":"Alto Neuroscience appoints Andrew Miller to board; former Karuna Therapeutics president","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Miller, Ph.D., appointed to board effective May 27, 2026, filling vacancy after board size increased to seven.","Miller founded Karuna Therapeutics and served as President of R&D until its acquisition by Bristol Myers Squibb in March 2024.","Appointed to the Nominating and Corporate Governance Committee, replacing Christopher Nixon Cox.","Initial option grant for up to 48,200 shares (Black-Scholes value ≤$400k); annual retainer $40k plus $5k for NCGC service.","Board determined Miller is independent under NYSE and SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68682,"accession_number":"0001999480-26-000014","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2026-05-13T20:21:06+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alto Neuroscience annual meeting: ESPP amendment approved, equity plan amendment fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2024 ESPP to treat pre-funded warrants as shares for evergreen feature.","Stockholders rejected amendment to 2024 Equity Incentive Plan to treat pre-funded warrants for share reserve calculation.","Directors Raymond Sanchez and Gwill York elected; 10.8M votes withheld for York.","Ratification of Deloitte & Touche LLP as independent auditor for FY 2026 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49921,"accession_number":"0001999480-26-000011","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2026-05-13T11:04:01+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alto Neuroscience Q1 net loss $26.2M; initiates Phase 2b trial for ALTO-207 in TRD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.2M for Q1 2026 vs $15.2M in Q1 2025; R&D expenses rose to $20.3M.","Cash and equivalents of $264.2M as of March 31, 2026, up from $177.0M after $120M PIPE closed in March.","Phase 2b trial of ALTO-207 in treatment-resistant depression (TRD) initiated; topline data expected 2H 2027.","ALTO-101 Phase 2 POC trial missed primary endpoint (theta-ITC) but showed significant EEG biomarker effects and attention improvement.","ALTO-300 and ALTO-100 Phase 2b topline data readouts delayed to 1H 2027 and mid-2027, respectively, due to enhanced patient eligibility review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97127,"accession_number":"0001104659-26-038593","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alto Neuroscience Phase 2 miss for ALTO-101; shifts focus to ALTO-207","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ALTO-101 did not meet primary EEG or cognitive endpoints in Phase 2 CIAS study.","Near-significant theta-ITC effect (p=0.052); nominal in cognitively impaired subgroup (p=0.03).","Company developed modified-release ALTO-101 formulation; will pursue partnerships, not further internal development.","ALTO-207 Phase 2b in treatment-resistant depression on track for 1H 2026; cash position $275M.","Tolerability favorable with nausea/vomiting in line with placebo; high skin reaction rates observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111658,"accession_number":"0001999480-26-000001","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alto Neuroscience reports FY2025 net loss $63.2M; cash $177M; ALTO-207 Phase 2b on track for 1H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents & restricted cash $177M as of Dec 31, 2025; runway into 2028 covers four key readouts.","Net loss of $63.2M for FY2025 vs $61.4M in FY2024; R&D expenses $45.6M, G&A $20.7M.","Acquired ALTO-207 (pramipexole/ondansetron) for TRD; Lancet-published PAX-D study showed Cohen's d=0.87 effect size.","ALTO-207 Phase 2b trial expected to start 1H 2026, topline data 2H 2027; $50M PIPE completed in October 2025.","ALTO-101 granted FDA Fast Track for CIAS; Phase 2 POC topline data expected around end of Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111657,"accession_number":"0001104659-26-027953","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Alto Neuroscience raises $120M via PIPE to fund ALTO-207 Phase 3 in TRD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$120M from sale of 2.9M shares at $20.00 and 3.1M pre-funded warrants at $19.9999.","Financing led by Commodore Capital with participation from new and existing biotech investors.","Proceeds to fund ALTO-207 (pramipexole/ondansetron combo) through planned Phase 3 TRD study and potential NDA.","Plan to initiate ALTO-207 Phase 2b in H1 2026 and Phase 3 in early 2027; pro forma cash ~$275M as of Feb 28, 2026.","Closing expected March 17, 2026; Jefferies, BofA, TD Cowen, Stifel, William Blair, Baird as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128293,"accession_number":"0001999480-25-000089","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alto Neuroscience Q3 net loss $14.2M; cash $184.2M after $50M PIPE; ALTO-207 on track for Phase 3 by early 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.2M vs $16.8M in Q3 2024; R&D expense $10.5M, G&A $4.4M.","Cash $184.2M as of Oct 31 (incl. $49.9M net PIPE proceeds), projected to fund operations into 2028.","ALTO-207 Phase 2b TRD trial start 1H 2026; Phase 3 by early 2027 after successful FDA meeting.","Topline data expected: ALTO-101 CIAS (1Q 2026), ALTO-300 MDD (mid-2026), ALTO-100 BPD (2H 2026).","ALTO-101 granted FDA Fast Track Designation for CIAS; blinded PK analyses showed 100% positivity."],"consensus_eps_estimate":-0.6811,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128292,"accession_number":"0001104659-25-100801","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["1.01","1.02","3.02","8.01","9.01"],"status":"ready","headline":"Alto Neuroscience raises $50M in PIPE; accelerates ALTO-207 in TRD after FDA meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$50M from PIPE led by Perceptive Advisors; priced at $5.914/share plus pre-funded warrants at $5.9139.","Proceeds to accelerate ALTO-207 development in treatment-resistant depression; Phase 2b potentially pivotal by mid-2026, Phase 3 by early 2027.","Successful FDA meeting for ALTO-207 guides accelerated path; blinded PK data from ALTO-100 and ALTO-101 showed 96% and 100% compliance.","Terminated $75M Sales Agreement with Leerink Partners; no shares sold under it.","Cash runway extended into 2028 including additional ALTO-207 activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145087,"accession_number":"0001999480-25-000075","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Alto Neuroscience Q2 net loss $17.7M; ALTO-207 acquisition expands TRD pipeline; data readouts ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.7M in Q2 2025 vs $16.0M in Q2 2024; cash $148.1M expected to fund operations into 2028.","Acquired ALTO-207 (pramipexole/ondansetron) from Chase; Phase 2b in TRD planned by mid-2026.","ALTO-101 Phase 2 POC topline data for CIAS expected 2H 2025; ALTO-300 Phase 2b MDD data mid-2026.","ALTO-100 Phase 2b bipolar depression data expected 2H 2026; ALTO-203 showed positive pharmacodynamic results.","Appointed Raymond Sanchez, M.D., to Board; class structure reconstituted, committee assignments updated."],"consensus_eps_estimate":-0.6253,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145086,"accession_number":"0001999480-25-000061","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alto Neuroscience reprices ~4.2M underwater options to $2.35 for employee retention","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Total eligible options: 4,225,763 shares repriced to $2.35 from original range $2.44-$16.00 per share.","CEO Amit Etkin: 719,910 options; CFO Nicholas Smith: 506,124; COO Michael Hanley: 321,000.","Reduced price applies only after 12-month retention period (or earlier on change in control or qualifying termination).","Number of shares, vesting schedules, and expiration dates remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163469,"accession_number":"0001999480-25-000053","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alto Neuroscience identifies EEG biomarker and positive Phase 2 results for ALTO-203 in MDD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ALTO-203 showed pro-cognitive and wake-promoting effects; EEG theta/beta ratio confirmed as key biomarker (25µg: p<0.05).","Improvements in sustained attention replicated Phase 1 findings; greatest in patients with high baseline theta/beta ratio (25µg: p<0.01; 75µg: p<0.05).","Objective sleep measures from wearables confirmed wake-promotion; both doses significant (25µg: p<0.05; 75µg: p<0.001 vs placebo).","MADRS improvements were small (25µg: -2 points at week 3 vs placebo) but trial not powered for significance.","Safety profile: well tolerated, insomnia most common adverse event; predictable PK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163468,"accession_number":"0001999480-25-000048","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Alto Neuroscience acquires two dopamine agonist candidates for TRD and Parkinson's","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Alto paid $1.75M cash plus $1.2M expense reimbursement upfront, with up to $71.5M in milestone payments ($41M commercial).","Acquired CTC-501 (renamed ALTO-207) for treatment-resistant depression and CTC-413 (ALTO-208) for Parkinson's disease.","Phase 2a of CTC-501 met primary endpoint; patients reached mean 4.1 mg/day, 67% achieved 5 mg, MADRS improvement d=1.1 (p=0.025).","Alto expects to initiate a potentially pivotal Phase 2b trial for ALTO-207 by mid-2026, with topline data in 2027.","Cash guidance unchanged; current cash expected to fund operations into 2028 through at least five planned clinical readouts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163467,"accession_number":"0001999480-25-000035","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Alto Neuroscience Q1 net loss $15.2M; cash $161.3M; key trial readouts on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.2M for Q1 2025 vs $13.4M in Q1 2024; R&D expense flat at $10.0M.","Cash, cash equivalents and restricted cash of $161.3M as of March 31, 2025, expected to fund operations into 2028.","ALTO-203 Phase 2 POC MDD trial topline data expected in Q2 2025; ALTO-101 Phase 2 CIAS data in H2 2025.","ALTO-300 Phase 2b MDD trial data expected mid-2026; ALTO-100 Phase 2b BPD trial data H2 2026.","At annual meeting, stockholders reelected Husseini Manji as Class I director and ratified Deloitte as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181386,"accession_number":"0001999480-25-000024","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Alto Neuroscience FY2024 net loss $61.4M; cash $169M; two directors departing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.4M for FY2024 vs $36.3M in 2023; R&D expense $47M, G&A $21.6M.","Cash and equivalents $169M as of Dec 31, 2024; expected to fund operations into 2028.","Directors Jeff Chen and Maha Radhakrishnan will not stand for re-election at 2025 annual meeting; board size to shrink from 7 to 5.","ALTO-300 Phase 2b MDD trial interim analysis positive; topline results expected mid-2026.","ALTO-203 Phase 2 MDD trial enrollment complete; topline data expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181385,"accession_number":"0001193125-25-024814","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alto Neuroscience reports favorable ALTO-300 Phase 2b interim analysis; final data expected mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Planned interim analysis recommended continuing study with ~200 biomarker-positive patients in final sample.","Topline results from the Phase 2b trial of ALTO-300 are expected in mid-2026.","Company reported preliminary 2024 year-end cash of ~$168M, expected to fund operations into 2028.","Interim analysis included 87 biomarker-positive patients after in-depth site and patient eligibility review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181384,"accession_number":"0001193125-25-019318","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Alto Neuroscience enters $75M ATM equity offering; reports ~$168M cash as of Dec 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into sales agreement with Leerink Partners for at-the-market offering of up to $75M in common stock.","Agent will receive up to 3.0% commission on shares sold; Company has no obligation to sell.","Preliminary cash and cash equivalents of ~$168M as of Dec 31, 2024; final year-end results may differ materially.","Registration statement on Form S-3 filed concurrently; ATM offering subject to SEC effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181383,"accession_number":"0001193125-25-007383","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Alto Neuroscience expands credit facility to $75M, extends maturity to 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity extended from Dec 2026 to Jan 2029; max facility raised from $35M to $75M.","$20M funded at closing; up to $30M tranche contingent on milestones, $25M tranche subject to lender approval.","Interest: Prime +1.45% (floor 8.45%) plus 1% PIK; cash runway covenant begins Jan 2026.","Loan conversion feature: up to $9M convertible at $10.49 (first $4M) and $4.8259 (next $5M).","Warrants repriced to $3.7122; new warrant issued for additional shares expiring Jan 2035."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198192,"accession_number":"0001999480-24-000040","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alto Neuroscience Q3 net loss $16.8M; ALTO-100 fails Phase 2b MDD primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.8M in Q3 2024 vs $9.1M a year ago; R&D expense $13.1M, G&A $5.8M.","Cash, cash equivalents & restricted cash ~$182M expected to fund operations into 2027.","ALTO-100 Phase 2b MDD missed primary endpoint; biomarker-positive mITT (n=196) not significant.","Adjunctive subgroup (n=61) showed clinically meaningful effect (Cohen's d=0.47, p=0.09); no MDD advancement planned.","Timelines: ALTO-300 & ALTO-203 topline 1H 2025; ALTO-101 topline 2H 2025; ALTO-100 bipolar depression topline 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198191,"accession_number":"0001193125-24-241092","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alto Neuroscience Phase 2b trial of ALTO-100 for MDD fails primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ALTO-100 did not show statistically significant improvement on MADRS vs placebo in biomarker-defined MDD patients.","Favorable safety and tolerability; no new signals; common AEs headache, nausea, abnormal dreams at rates similar to placebo.","ALTO-100 also in Phase 2b for bipolar depression; cash expected to fund operations into 2027 with other readouts in H1 2025.","Company will analyze full dataset to determine next steps for ALTO-100 in MDD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214315,"accession_number":"0001999480-24-000033","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alto Neuroscience Q2 2024 net loss $16.0M; cash $193.6M; Phase 2b MDD topline due Oct 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and restricted cash of $193.6M as of June 30, 2024; expected to fund operations into 2027.","Net loss of $16.0M for Q2 2024 vs $8.7M in Q2 2023; R&D expenses rose to $13.2M from $7.1M.","Completed enrollment of 301 patients in Phase 2b MDD study of ALTO-100; topline data expected in October 2024.","Initiated Phase 2 studies: ALTO-101 in schizophrenia CIAS, ALTO-203 in MDD with anhedonia, ALTO-100 in bipolar depression.","Received $11.7M Wellcome Trust award for ALTO-100 in bipolar depression; added COO Michael Hanley."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214314,"accession_number":"0001999480-24-000025","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Alto Neuroscience secures up to $11.7M convertible loan from Wellcome for ALTO-100 Phase 2b trial","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $11.663M convertible loan from Wellcome Trust; $2M funded immediately, remainder upon milestones.","Interest accrues at SONIA+2%; convertible into common stock at 20% discount to 30-day VWAP after 2nd anniversary.","Conversion shares capped at 5,363,326 (19.9% of outstanding stock).","Proceeds used exclusively to fund ALTO-100 Phase 2b clinical trial in bipolar depression."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233544,"accession_number":"0001193125-24-143369","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alto Neuroscience appoints Michael Hanley as Chief Operating Officer effective May 20, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hanley receives $470,000 base salary, 40% annual performance bonus target, and option for 188,000 shares.","Option vests 25% on 1-year anniversary, then monthly over 4 years, subject to continuous service.","Severance: 9 months salary plus COBRA on non-cause termination; 12 months salary, bonus, and full equity acceleration upon change in control termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233543,"accession_number":"0001999480-24-000020","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alto Neuroscience Q1 net loss $13.4M; cash $205.9M; pipeline on track for multiple readouts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.4M vs $7.3M YoY; R&D expenses $10.0M, G&A $4.4M, both up on clinical study costs and public company expenses.","Cash and equivalents $205.9M as of March 31, 2024; expects to fund operations into 2027.","Initiated Phase 2 study of ALTO-203 in MDD with anhedonia; reported positive Phase 1 data for transdermal ALTO-101 with improved tolerability.","Phase 2b studies of ALTO-100 and ALTO-300 in MDD enrolling; topline data for ALTO-100 expected 2H 2024, ALTO-300 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251620,"accession_number":"0001999480-24-000008","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alto Neuroscience FY2023 net loss $36.3M; cash ~$210M post-IPO; Phase 2b MDD studies on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $36.3M in FY2023 (vs $27.7M in 2022); R&D spend $30.3M, G&A $7.5M.","Cash $82.5M at Dec 31, 2023; post-IPO net proceeds ~$133M, cash ~$210M as of Feb 29, 2024.","ALTO-100 Phase 2b MDD enrollment ongoing; topline data 2H 2024. ALTO-300 Phase 2b data 1H 2025.","Appointed Drs. Maha Radhakrishnan (ex-Biogen CMO) and Husseini Manji (ex-J&J) to board.","CIRM approved $15M grant for ALTO-100 Phase 2b in bipolar depression; initiation planned 2024 subject to terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251619,"accession_number":"0001193125-24-064372","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alto Neuroscience appoints former Biogen CMO Maha Radhakrishnan to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Radhakrishnan, age 54, appointed as Class I director effective March 8, 2024; term expires at 2025 Annual Meeting.","Former Group SVP and Chief Medical Officer at Biogen (Jan 2020 – Mar 2024); earlier roles at Sanofi and Bioverativ.","Board determined she is independent under NYSE and SEC rules; will serve on Nominating and Corporate Governance Committee.","Receives initial option for 30,574 shares vesting over 3 years, annual option for 15,287 shares, and cash retainers ($40k board + $5k NCGC).","Company entered standard indemnification agreement with Dr. Radhakrishnan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251618,"accession_number":"0001193125-24-025266","cik":1999480,"company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Alto Neuroscience files amended charter and bylaws effective upon IPO closing on Feb 6, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended and restated certificate of incorporation filed with Delaware Secretary of State on Feb 6, 2024.","Amended and restated bylaws adopted effective Feb 6, 2024, in connection with IPO closing.","Both documents previously approved by board and stockholders; no changes to fiscal year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":709424030.1323384,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}